The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease

Journal of Pathology

Volumn 245, Issue 1, 2018, Pages 85-100

  Batista, Andre F ^a   Forny Germano, Leticia ^a   Clarke, Julia R ^a   Lyra e Silva, Natalia M ^a   Brito Moreira, Jordano ^a   Boehnke, Susan E ^b   Winterborn, Andrew ^c   Coe, Brian C ^b   Lablans, Ann ^b   Vital, Juliana F ^a   Marques, Suelen A ^d   Martinez, Ana MB ^a   Gralle, Matthias ^a   Holscher, Christian ^e   Klein, William L ^f   Houzel, Jean Christophe ^a   Ferreira, Sergio T ^a   Munoz, Douglas P ^b   De Felice, Fernanda G ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b QUEEN S UNIVERSITY   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^e LANCASTER UNIVERSITY   (United Kingdom)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; diabetes; GLP 1; insulin receptors; liraglutide; neurodegeneration; non human primates; PKA signaling; synapse damage; tau pathology

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; DISKS LARGE HOMOLOG 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LIRAGLUTIDE; OLIGOMER; SYNAPTOPHYSIN; TAU PROTEIN; AMYLOID BETA PROTEIN; ANTIDIABETIC AGENT;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME ACTIVATION; HIPPOCAMPAL NEURONAL CULTURE; LATERAL BRAIN VENTRICLE; MALE; MEMORY DISORDER; MOUSE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNAPSE; SYSTEMIC THERAPY; ANIMAL; DISEASE MODEL; DRUG EFFECT; HIPPOCAMPUS; MEMORY; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; COGNITIVE DYSFUNCTION; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MEMORY; MICE; RECEPTOR, INSULIN; SYNAPSES;

EID: 85044629495     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.5056     Document Type: Article

References (117)

1. Ott A, Stolk RP, Hofman A, et al. Association of diabetes mellitus and dementia: the Rotterdam study. Diabetologia 1996; 39: 1392–1397.
2. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes – evidence reviewed. J Diabetes Sci Technol 2008; 2: 1101–1113.
3. Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 2011; 71: 365–376.
4. De Felice FG. Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J Clin Invest 2013; 123: 531–539.
5. Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 2012; 122: 1339-1353.
6. Moloney AM, Griffin RJ, Timmons S, et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010; 31: 224–243.
7. De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 2009; 106: 1971–1976.
8. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122: 1316–1338.
9. Lee CC, Kuo YM, Huang CC, et al. Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. Neurobiol Aging 2009; 30: 377–387.
10. Lee S, Tong M, Hang S, et al. CSF and brain indices of insulin resistance, oxidative stress and neuro-inflammation in early versus late Alzheimer's disease. J Alzheimers Dis Parkinsonism 2013; 3: 128.
11. Wadman M. US government sets out Alzheimer's plan. Nature 2012; 485: 426–427.
12. Craft S. Alzheimer disease: insulin resistance and AD – extending the translational path. Nat Rev Neurol 2012; 8: 360–362.
13. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012; 69: 29–38.
14. Cholerton B, Baker LD, Craft S. Insulin, cognition, and dementia. Eur J Pharmacol 2013; 719: 170–179.
15. Cholerton B, Baker LD, Montine TJ, et al. Type 2 diabetes, cognition, and dementia in older adults: toward a precision health approach. Diabetes Spectr 2016; 29: 210–219.
16. Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab 2013; 24: 85–91.
17. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173–1179.
18. Hsu TM, Hahn JD, Konanur VR, et al. Hippocampal GLP-1 receptors influence food intake, meal size, and effort-based responding for food through volume transmission. Neuropsychopharmacology 2015; 40: 327–337.
19. Richards P, Parker HE, Adriaenssens AE, et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 2014; 63: 1224–1233.
20. Cork SC, Richards JE, Holt MK, et al. Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab 2015; 4: 718–731.
21. Alvarez E, Martinez MD, Roncero I, et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 2005; 92: 798–806.
22. Abbas T, Faivre E, Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res 2009; 205: 265–271.
23. Mattson MP, Perry T, Greig NH. Learning from the gut. Nat Med 2003; 9: 1113–1115.
24. Holscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 2012; 26: 871–882.
25. Gault VA, Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 2008; 587: 112–117.
26. McClean PL, Gault VA, Harriott P, et al. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010; 630: 158–162.
27. Lourenco MV, Clarke JR, Frozza RL, et al. TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's beta-amyloid oligomers in mice and monkeys. Cell Metab 2013; 18: 831–843.
28. McClean PL, Parthsarathy V, Faivre E, et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011; 31: 6587–6594.
29. Li Y, Duffy KB, Ottinger MA, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010; 19: 1205–1219.
30. McClean PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 2014; 76(Pt A): 57–67.
31. Qi L, Ke L, Liu X, et al. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced Alzheimer disease mouse model. Eur J Pharmacol 2016; 783: 23–32.
32. Hansen HH, Fabricius K, Barkholt P, et al. The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer's disease. J Alzheimers Dis 2015; 46: 877–888.
33. Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003; 72: 603–612.
34. Yang Y, Zhang J, Ma D, et al. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J Alzheimers Dis 2013; 37: 637–648.
35. Chen S, Sun J, Zhao G, et al. Liraglutide improves water maze learning and memory performance while reduces hyperphosphorylation of tau and neurofilaments in APP/PS1/tau triple transgenic mice. Neurochem Res 2017; 42: 2326–2335.
36. Qi L, Chen Z, Wang Y, et al. Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3beta. Am J Transl Res 2017; 9: 247–260.
37. Mansur RB, Ahmed J, Cha DS, et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord 2017; 207: 114–120.
38. Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390: 1664–1675.
39. Athauda D, Wyse R, Brundin P, et al. Is exenatide a treatment for Parkinson's disease? J Parkinsons Dis 2017; 7: 451–458.
40. Cha DS, Vahtra M, Ahmed J, et al. Repurposing of anti-diabetic agents for the treatment of cognitive impairment and mood disorders. Curr Mol Med 2016; 16: 465–473.
41. Vilsboll T, Krarup T, Madsbad S, et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114: 115–121.
42. Winnay JN, Solheim MH, Dirice E, et al. PI3-kinase mutation linked to insulin and growth factor resistance in vivo. J Clin Invest 2016; 126: 1401–1412.
43. Gong Y, Chang L, Viola KL, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 2003; 100: 10417–10422.
44. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837–842.
45. Zhao WQ, De Felice FG, Fernandez S, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008; 22: 246–260.
46. Norambuena A, Wallrabe H, McMahon L, et al. mTOR and neuronal cell cycle reentry: how impaired brain insulin signaling promotes Alzheimer's disease. Alzheimers Dement 2017; 13: 152–167.
47. Forny-Germano L, Lyra e Silva NM, Batista AF, et al. Alzheimer's disease-like pathology induced by amyloid-β oligomers in nonhuman primates. J Neurosci 2014; 34: 13629–13643.
48. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998; 95: 6448–6453.
49. Figueiredo CP, Clarke JR, Ledo JH, et al. Memantine rescues transient cognitive impairment caused by high-molecular-weight Aβ oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci 2013; 33: 9626–9634.
50. Jurgensen S, Antonio LL, Mussi GE, et al. Activation of D1/D5 dopamine receptors protects neurons from synapse dysfunction induced by amyloid-beta oligomers. J Biol Chem 2011; 286: 3270–3276.
51. Sebollela A, Freitas-Correa L, Oliveira FF, et al. Amyloid-beta oligomers induce differential gene expression in adult human brain slices. J Biol Chem 2012; 287: 7436–7445.
52. De Felice FG, Wu D, Lambert MP, et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers. Neurobiol Aging 2008; 29: 1334–1347.
53. De Felice FG, Wasilewska-Sampaio AP, Barbosa AC, et al. Cyclic AMP enhancers and Aβ oligomerization blockers as potential therapeutic agents in Alzheimer's disease. Curr Alzheimer Res 2007; 4: 263–271.
54. Ledo JH, Azevedo EP, Clarke JR, et al. Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice. Mol Psychiatry 2013; 18: 1053–1054.
55. Clarke JR, Lyra E Silva NM, Figueiredo CP, et al. Alzheimer-associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Mol Med 2015; 7: 190–210.
56. Nirmalan NJ, Harnden P, Selby PJ, et al. Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using western blotting. J Pathol 2009; 217: 497–506.
57. Christopherson KS, Ullian EM, Stokes CC, et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 2005; 120: 421–433.
58. Long-Smith CM, Manning S, McClean PL, et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromol Med 2013; 15: 102–114.
59. Perry T, Haughey NJ, Mattson MP, et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002; 302: 881–888.
60. De Felice FG, Velasco PT, Lambert MP, et al. Aβ oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007; 282: 11590–11601.
61. Schirra J, Sturm K, Leicht P, et al. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998; 101: 1421–1430.
62. Abel T, Kandel E. Positive and negative regulatory mechanisms that mediate long-term memory storage. Brain Res Brain Res Rev 1998; 26: 360–378.
63. Kandel ER. The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB. Mol Brain 2012; 5: 14.
64. Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc Drug Rev 2006; 24: 261–274.
65. Murray AJ. Pharmacological PKA inhibition: all may not be what it seems. Sci Signal 2008; 1: re4.
66. Barker GR, Warburton EC. When is the hippocampus involved in recognition memory? J Neurosci 2011; 31: 10721–10731.
67. Chiu SL, Chen CM, Cline HT. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 2008; 58: 708–719.
68. Grillo CA, Piroli GG, Lawrence RC, et al. Hippocampal insulin resistance impairs spatial learning and synaptic plasticity. Diabetes 2015; 64: 3927–3936.
69. Ferris HA, Kahn CR. Unraveling the paradox of selective insulin resistance in the liver: the brain–liver connection. Diabetes 2016; 65: 1481–1483.
70. Biessels GJ, Reagan LP. Hippocampal insulin resistance and cognitive dysfunction. Nat Rev Neurosci 2015; 16: 660–671.
71. Fadel JR, Reagan LP. Stop signs in hippocampal insulin signaling: the role of insulin resistance in structural, functional and behavioral deficits. Curr Opin Behav Sci 2016; 9: 47–54.
72. Heppner KM, Kirigiti M, Secher A, et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 2015; 156: 255–267.
73. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990; 27: 457–464.
74. Scheff SW, Price DA. Synapse loss in the temporal lobe in Alzheimer's disease. Ann Neurol 1993; 33: 190–199.
75. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572–580.
76. Martinez-Coria H, Green KN, Billings LM, et al. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 2010; 176: 870–880.
77. Espinoza M, de Silva R, Dickson DW, et al. Differential incorporation of tau isoforms in Alzheimer's disease. J Alzheimers Dis 2008; 14: 1–16.
78. Guerrero-Munoz MJ, Gerson J, Castillo-Carranza DL. Tau oligomers: the toxic player at synapses in Alzheimer's disease. Front Cell Neurosci 2015; 9: 464.
79. Patterson KR, Remmers C, Fu Y, et al. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem 2011; 286: 23063–23076.
80. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2012; 2: 700.
81. Sengupta U, Portelius E, Hansson O, et al. Tau oligomers in cerebrospinal fluid in Alzheimer's disease. Ann Clin Transl Neurol 2017; 4: 226–235.
82. Tai HC, Serrano-Pozo A, Hashimoto T, et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin–proteasome system. Am J Pathol 2012; 181: 1426–1435.
83. Fa M, Puzzo D, Piacentini R, et al. Extracellular tau oligomers produce an immediate impairment of LTP and mMemory. Sci Rep 2016; 6: 19393.
84. Li S, Hong S, Shepardson NE, et al. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009; 62: 788–801.
85. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 2016; 8: 595–608.
86. Lee HK, Kwon B, Lemere CA, et al. mTORC2 (Rictor) in Alzheimer's disease and reversal of amyloid-β expression-induced insulin resistance and toxicity in rat primary cortical neurons. J Alzheimers Dis 2017; 56: 1015–1036.
87. De Felice FG, Munoz DP. Opportunities and challenges in developing relevant animal models for Alzheimer's disease. Ageing Res Rev 2016; 26: 112–114.
88. Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016; 537: 50–56.
89. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nat Rev Neurol 2010; 6: 108–119.
90. Vitolo OV, Sant'Angelo A, Costanzo V, et al. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A 2002; 99: 13217–13221.
91. Wang QW, Rowan MJ, Anwyl R. Inhibition of LTP by beta-amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP/PKA signalling pathway. Neurobiol Aging 2009; 30: 1608–1613.
92. Liang Z, Liu F, Grundke-Iqbal I, et al. Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. J Neurochem 2007; 103: 2462–2470.
93. Kim SH, Nairn AC, Cairns N, et al. Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease. J Neural Transm Suppl 2001; 263–272.
94. Rosenberger AF, Hilhorst R, Coart E, et al. Protein kinase activity decreases with higher Braak stages of Alzheimer's disease pathology. J Alzheimers Dis 2016; 49: 927–943.
95. Bartolotti N, Bennett DA, Lazarov O. Reduced pCREB in Alzheimer's disease prefrontal cortex is reflected in peripheral blood mononuclear cells. Mol Psychiatry 2016; 21: 1158–1166.
96. van der Harg JM, Eggels L, Bangel FN, et al. Insulin deficiency results in reversible protein kinase A activation and tau phosphorylation. Neurobiol Dis 2017; 103: 163–173.
97. Hong S, Beja-Glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016; 352: 712–716.
98. Diniz LP, Tortelli V, Matias I, et al. Astrocyte transforming growth factor beta 1 protects synapses against Aβ oligomers in Alzheimer's disease model. J Neurosci 2017; 37: 6797–6809.
99. Brito-Moreira J, Lourenco MV, Oliveira MM, et al. Interaction of amyloid-beta (Aβ) oligomers with neurexin 2α and neuroligin 1 mediates synapse damage and memory loss in mice. J Biol Chem 2017; 292: 7327–7337.
100. Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 2014; 82: 756–771.
101. Davies CA, Mann DM, Sumpter PQ, et al. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987; 78: 151–164.
102. Scheff SW, Price DA. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging 2003; 24: 1029–1046.
103. Scheff SW, Price DA. Synaptic density in the inner molecular layer of the hippocampal dentate gyrus in Alzheimer disease. J Neuropathol Exp Neurol 1998; 57: 1146–1153.
104. Abbott MA, Wells DG, Fallon JR. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J Neurosci 1999; 19: 7300–7308.
105. Chiu SL, Cline HT. Insulin receptor signaling in the development of neuronal structure and function. Neural Dev 2010; 5: 7.
106. Claxton A, Baker LD, Hanson A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis 2015; 44: 897–906.
107. Freiherr J, Hallschmid M, Frey WH 2nd, et al. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013; 27: 505–514.
108. Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 2008; 13: 323–331.
109. Gancheva S, Koliaki C, Bierwagen A, et al. Effects of intranasal insulin on hepatic fat accumulation and energy metabolism in humans. Diabetes 2015; 64: 1966–1975.
110. Benedict C, Hallschmid M, Schmitz K, et al. Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 2007; 32: 239–243.
111. Seixas da Silva GS, Melo HM, Lourenco MV, et al. Amyloid-beta oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons. J Biol Chem 2017; 292: 7395–7406.
112. Vandal M, White PJ, Tremblay C, et al. Insulin reverses the high-fat diet-induced increase in brain Aβ and improves memory in an animal model of Alzheimer disease. Diabetes 2014; 63: 4291–4301.
113. Chen Y, Zhao Y, Dai CL, et al. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice. Exp Neurol 2014; 261: 610–619.
114. Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov Today 2016; 21: 802–818.
115. Sandoval D. CNS GLP-1 regulation of peripheral glucose homeostasis. Physiol Behav 2008; 94: 670–674.
116. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011; 34(suppl 2): S279–S284.
117. Gejl M, Gjedde A, Egefjord L, et al. In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci 2016; 8: 108.